Nothing has changed!, page-11

With what we now know, being that there were no issues reported on the clinical side, ahead of the final sign off on June 24, the share price, all things being equal, should be above 18c. If you liked it at 18c with all components of approval being unknown, you should really like it now. The most costly and the highest risk component appears done.

Acknowledging of course that there is now a delay and some folks will price that in. Today that looks like 4c. The greatest approval risk and cost, being clinical, is done. That is information we didn’t have last week. We now do. Again, all else being equal, it’s logical that the stock trades higher into the next approval cycle.

There may have been a management oversight here, maybe they were a bit too relaxed and optimised, but it’s hard to pinpoint. If this is the case, it’s incredibly frustrating.

But once bitten twice shy, and I doubt Howie stake his career on what by his own admission, is not a complex task to complete. He will nail this.

I believe they will work harder than ever to make this right, will get it right, and it will be approved.

rock on.